Studies have suggested that high expression of Histone deacetylase (HDAC) in childhood T-ALL is associated with poor prognosis, which indicates that HDAC inhibitors (HDACis) may be used to treat T-ALL (7). The gene discussed is HDAC9; the disease is acute lymphoblastic leukemia.